25 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
2 Aug 23
Report of Foreign Private Issuer
8:05am
during the peak of the COVID-19 pandemic. 19 out of the 21 treated patients had mild-to-severe ARDS with their COVID-19. The Phase I/II clinical
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
22 Nov 21
Enlivex Announces Third Quarter 2021 Financial Results and Provides a Business Update
8:00am
in an effort to further expand the trial in Europe as part of its regulatory strategy. Due to the impact of COVID-19 pandemic on trial enrollment to-date … :
Enlivex believes that COVID-19 will transition from a pandemic to an endemic, with multiple variants continuing to circulate throughout
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
19 Nov 21
Condensed Consolidated Financial Statements
4:30pm
clinical development programs may be extended due to direct and indirect impacts of the COVID-19 pandemic or new variants of the virus. For example … sepsis due to a lower number of pneumonic septic patients, as a result of the COVID-19 pandemic environment. The Company previously reported
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
19 Nov 21
Condensed Consolidated Financial Statements
4:30pm
to direct and indirect impacts of the COVID-19 pandemic or new variants of the virus. For example, there has been a delay in recruiting patients … patients, as a result of the COVID-19 pandemic environment. The Company previously reported that the Company expected to obtain interim results from
6-K
EX-99.1
ywm 4nl3seswv0c8cofe
22 Sep 21
Report of Foreign Private Issuer
6:02am
6-K
EX-99.1
e5gkpqc3q2c43edud
16 Aug 21
Report of Foreign Private Issuer
6:12am
6-K
EX-99.1
6vp9fh5s80kx
9 Aug 21
Enlivex Announces Second Quarter 2021 Financial Results and Provides a Business Update
8:00am
6-K
EX-99.2
qaf62i89
6 Aug 21
Condensed Consolidated Financial Statements
4:31pm
6-K
EX-99.1
ff4udj
6 Aug 21
Condensed Consolidated Financial Statements
4:31pm
6-K
EX-99.1
940humkyyvjp2a1peoe
28 May 21
Condensed Consolidated Financial Statements
4:33pm
6-K
EX-99.2
duj0s7
28 May 21
Condensed Consolidated Financial Statements
4:33pm
6-K
EX-99.1
ji2sh 7tz
3 Feb 21
Current Report
7:55am
6-K
EX-99.1
rb56 442xkve
3 Dec 20
Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
8:00am
6-K
EX-99.2
29ny9s1 jphl
30 Oct 20
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
e1ul5a
30 Oct 20
Condensed Consolidated Financial Statements
4:30pm
6-K/A
EX-99.2
k0fcrfmd
13 Oct 20
Condensed Consolidated Financial Statements
9:16am
6-K/A
EX-99.1
8cdyeq
13 Oct 20
Condensed Consolidated Financial Statements
9:16am
6-K
EX-99.1
rskmoh slix1ee8
1 Oct 20
Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition
6:06am